ANIX (Anixa Biosciences) GF Value Rank: 2 (As of Jul. 11, 2026) — 100% Above Median


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $3.07
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences GF Value Rank?

Anixa Biosciences ANIX -4.52% 27 GF Value Rank is 2 as of Jul. 11, 2026, which is 100% above its 10-year median of 1.00. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

Anixa Biosciences has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Anixa Biosciences GF Value Rank Related Terms

ANIX vs BMEA, PMN, ATRA: GF Value Rank Comparison

For the Biotechnology subindustry, Anixa Biosciences's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anixa Biosciences GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's GF Value Rank falls into.


ANIX
27GF Score
Anixa Biosciences Inc ANIX
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Anixa Biosciences (ANIX) has a GF Value Rank of 2 as of Jul. 11, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Anixa Biosciences and its competitors. This is 100% above median its historical median of 1.00. Over the past decade, Anixa Biosciences' GF Value Rank has ranged from 1.00 to 10.00.
Is Anixa Biosciences' GF Value Rank too high?
Anixa Biosciences' current GF Value Rank of 2 is 100% above median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' GF Value Rank compare to BMEA and PMN?
Anixa Biosciences' GF Value Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Anixa Biosciences' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current GF Value Rank is 2, which is 100% above median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current GF Value Rank of 2. The current GF Value Rank is 2, which is 100% above median its 10-year median of 1.00. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current GF Value Rank is 2 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.07
Price